HPV vaccine protection and better cervical cancer screening for women with HIV
Real-world effectiveness of HPV vaccine in women living with HIV and its impact on cervical cancer screening accuracies
Checking whether the HPV vaccine protects women living with HIV and which cervical screening methods work best for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11336383 on NIH RePORTER |
What this research studies
You would be part of work using existing clinical data and stored samples from women living with HIV to see how well the HPV vaccine prevents the infections that can lead to cervical cancer. Researchers will compare vaccinated and unvaccinated participants and review past screening results to measure how screening tests perform in this group. They will also test newer lab markers (like p16/Ki‑67 staining, extended HPV genotyping, and DNA methylation) on samples to find which approaches better detect pre-cancer. The effort is done through the Pediatric HIV/AIDS Cohort Study network and linked clinical sites.
Who could benefit from this research
Good fit: Women living with HIV—particularly adolescents and young adults, including those perinatally infected, with known HPV vaccination or screening histories—are the ideal candidates.
Not a fit: People without HIV, men, or women with no available vaccination or screening records are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, the work could confirm whether vaccination protects women with HIV and help make cervical screening more accurate so precancer is found earlier and unnecessary procedures are reduced.
How similar studies have performed: Prior studies suggest primary HPV testing with genotyping can reduce unnecessary colposcopies, but vaccine effectiveness and newer biomarkers like p16/Ki‑67 and methylation are still largely untested in women living with HIV.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Moscicki, Anna-Barbara — University of California Los Angeles
- Study coordinator: Moscicki, Anna-Barbara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.